Nav: Home

New research insights hold promise for kids with DMD

February 11, 2019

WASHINGTON-(Feb. 11, 2019)-Prednisone, the current standard of care used to treat kids with Duchenne muscular dystrophy (DMD), reduces chronic inflammation but has harsh side effects. Eplerenone, a heart failure drug, is used in older patients to treat cardiomyopathy, a leading cause of mortality for people with DMD. A new medicine under development appears to combine the beneficial effects of these drugs for the heart and muscle while also showing improved safety in experimental models. This drug, vamorolone, does so by simultaneously targeting two nuclear receptors important in regulating inflammation and cardiomyopathy, indicates a small study published online Feb. 11, 2019, in Life Science Alliance.

DMD is a progressive X-linked disease that occurs mostly in males. It is characterized by muscle weakness that worsens over time, and most kids with DMD will use wheelchairs by the time they're teenagers. DMD is caused by mutations in the DMD gene, which provides instructions for making dystrophin, a protein found mostly in skeletal, respiratory and heart muscles.

Cardiomyopathy, an umbrella term for diseases that weaken the heart, is a leading cause of death for young adults with DMD, causing up to 50 percent of deaths in patients who lack dystrophin. A collaborative research team co-led by Christopher R. Heier, Ph.D., and Christopher F. Spurney, M.D., of Children's National Health System, is investigating cardiomyopathy in DMD. They find genetic dystrophin loss provides "a second hit" for a specific pathway that worsens cardiomyopathy in experimental models of DMD.

"Some drugs can interact with both the mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) since these two drug targets evolved from a common ancestor. However, we find these two drug targets can play distinctly different roles in heart and skeletal muscle. The GR regulates muscle inflammation, while the MR plays a key role in heart health," says Heier, an assistant professor at Children's National and lead study author. "In our study, the experimental drug vamorolone safely targets both the GR to treat chronic inflammation and the MR to treat the heart."

After gauging the efficacy of various treatments in test tubes, the study team looked at whether any could mitigate negative impacts of the MR on heart health. Wild type and mdx experimental models were implanted with pumps that activated the MR. These models also received a daily oral MR antagonist (or inhibitor) drug, and either eplerenone, spironolactone or vamorolone. Of note:
  • MR activation increased kidney size and caused elevated blood pressure (hypertension).
  • Treatment with vamorolone maintained normal kidney size and prevented hypertension.
  • MR activation increased mdx heart mass and fibrosis. Vamorolone mitigated these changes.
  • MR activation decreased mdx heart function, while vamorolone prevented declines in function.
  • Daily prednisone caused negative MR- and GR-mediated side effects, such as hyperinsulinemia, whereas vamorolone safely improved heart function without these side effects.
"These findings have the potential to help current and future patients," Heier says. "Clinicians already prescribe several of these drugs. Our new data support the use of MR antagonists such as eplerenone in protecting DMD hearts, particularly if patients take prednisone. The experimental drug vamorolone is currently in Phase IIb clinical trials and is particularly exciting for its unique potential to simultaneously treat chronic inflammation and heart pathology with improved safety."
-end-
In addition to Heier and Senior Author Spurney, study co-authors include Qing Yu, Alyson A. Fiorillo, Christopher B. Tully, Asya Tucker and Davi A. Mazala, all of Children's National; Kitipong Uaesoontrachoon and Sadish Srinivassane, AGADA Biosciences Inc.; and Jesse M. Damsker, Eric P. Hoffman and Kanneboyina Nagaraju, ReveraGen BioPharma.

Financial support for research described in this report was provided by Action Duchenne; the Clark Charitable Foundation; the Department of Defense under award W81XWH-17-1-047; the Foundation to Eradicate Duchenne; the Intellectual and Developmental Disabilities Research Center under award U54HD090257 (through the National Institutes of Health's (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development); and the NIH under awards K99HL130035, R00HL130035, L40AR068727 and T32AR056993.

Financial disclosure: Co-authors employed by ReveraGen BioPharma were involved in creating this news release.

Children's National Health System

Related Cardiomyopathy Articles:

Researchers develop faster and cheaper cardiac imaging test for developing countries
Researchers in the UK and Peru have developed a faster and cheaper cardiac imaging test that can be used in developing countries, according to the results of the INCA-Peru study presented today at EuroCMR 2017.
Do men have worse chemotherapy-induced cardiomyopathy than women?
Men seem to have worse chemotherapy-induced cardiomyopathy than women despite receiving similar cancer treatments, according to research presented today at EuroCMR 2017.
Spectrum Health Cardiomyopathy Program named National Center of Excellence
The Spectrum Health Hypertrophic Cardiomyopathy Program has been designated a national Center of Excellence by the Hypertrophic Cardiomyopathy Association (HCMA).
Peripartum cardiomyopathy occurs globally and is not a disease of the poor
Peripartum cardiomyopathy occurs globally and is not a disease of the poor, according to research published today in the European Journal of Heart Failure.
Identifying genetic variant early helps in treating hypertrophic cardiomyopathy in South Asians
Early screening for a genetic variant that predisposes people of South Asian descent to hypertrophic cardiomyopathy (an enlarged heart) could help reduce the incidence of sudden cardiac death in this population, says a University of Cincinnati College of Medicine heart researcher.
Marijuana use may be linked to temporarily weakened heart muscle
Younger marijuana users were twice as likely as non-users to experience stress cardiomyopathy, a sudden, usually temporary, weakening of the heart muscle that occurs more commonly in older women.
Sudden death in hypertrophic cardiomyopathy rarely associated with exercise
Sudden death in patients with hypertrophic cardiomyopathy (HCM) is rarely associated with exercise, according to research presented at ESC Congress 2016 today by Dr.
Hypertrophic cardiomyopathy under-appreciated cause of sudden cardiac death in male minority athletes
Sudden deaths in young, seemingly healthy competitive athletes are tragic events.
New disease gene will lead to better screening for pediatric heart disease
Cardiomyopathy, or a deterioration of the ability of the heart muscle to contract, generally leads to progressive heart failure.
FSU researcher targets on-off switch of cardiac contraction
Jose Pinto, a researcher in the Florida State University College of Medicine, will use a $1.8 million National Institutes of Health grant to study how the heart's calcium is regulated and how to correct a calcium imbalance using an inside approach in the cardiac cell.

Related Cardiomyopathy Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Bias And Perception
How does bias distort our thinking, our listening, our beliefs... and even our search results? How can we fight it? This hour, TED speakers explore ideas about the unconscious biases that shape us. Guests include writer and broadcaster Yassmin Abdel-Magied, climatologist J. Marshall Shepherd, journalist Andreas Ekström, and experimental psychologist Tony Salvador.
Now Playing: Science for the People

#513 Dinosaur Tails
This week: dinosaurs! We're discussing dinosaur tails, bipedalism, paleontology public outreach, dinosaur MOOCs, and other neat dinosaur related things with Dr. Scott Persons from the University of Alberta, who is also the author of the book "Dinosaurs of the Alberta Badlands".